EBS — Emergent BioSolutions Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1367644 ·
Last close
$5.61
Market Cap
$288.44M
52W High
$14.06
52W Low
$4.36
ADV30
1,049,610
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 106,400,000 | 25,600,000 | -37,300,000 | -32,700,000 | 995,200,000 | 175,700,000 | 682,000,000 |
| Jun 2026 | 226,800,000 | 129,700,000 | 66,200,000 | -180,200,000 | 1,116,800,000 | 139,700,000 | 775,400,000 |
| Mar 2026 | 149,700,000 | 77,700,000 | 10,500,000 | 6,800,000 | 1,320,400,000 | 160,300,000 | 797,300,000 |
| Dec 2025 | 143,800,000 | 58,900,000 | -15,700,000 | -54,600,000 | 1,318,600,000 | 205,400,000 | 796,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$200,100,000
Investing CF
$-54,000,000
Financing CF
$-218,400,000
CapEx
$-11,700,000
Dividends Paid
—
Buybacks
$-27,200,000
EPS Diluted TTM
$-5.10
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-365,900,000
Inventory
$280,900,000
Receivables
$77,500,000
ST Investments
—
EBIT TTM
$-194,600,000
Pretax Income TTM
$-240,000,000
Interest Exp TTM
$45,400,000
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$649,100,032
EBITDA
$125,700,000
Free Cash Flow
$196,687,504
Enterprise Value
$649,576,000
Total Cash
$175,700,000
Total Debt
$513,700,000
Shares Out
51,415,182
Trailing EPS
$-5.00
Book Value
$6.11
ROE
-58.2%
ROA
1.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 705,200,000 | 112,300,000 | 52,600,000 | 1,318,600,000 | 796,000,000 | 522,600,000 | 170,600,000 |
| Dec 2024 | 1,013,600,000 | -81,500,000 | -190,600,000 | 1,389,700,000 | 906,900,000 | 482,800,000 | 58,700,000 |
| Dec 2023 | 1,023,000,000 | -201,500,000 | -760,500,000 | 1,823,200,000 | 1,173,900,000 | 649,300,000 | -206,300,000 |
| Dec 2022 | 1,076,100,000 | -163,300,000 | -211,600,000 | 3,166,300,000 | 1,778,600,000 | 1,387,700,000 | -34,100,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,116,800,000
Forward EPS
$1.05
Max Pain — expiry 2027-01-15
max pain strike: $6.00 · spot: $5.50 · call oi: 5,091 · put oi: 567
Expected Move to 2027-01-15:
±$1.28
(23.18%) —
implied range
$4.22 –
$6.78
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | $286.78M | $6.57 | — |
| EVMN | Evommune, Inc. | $290.28M | $7.02 | — |
| FULC | Fulcrum Therapeutics, Inc. | $286.43M | $3.75 | — |
| VCRE | Vicore Pharma Holding AB | $285.02M | $10.12 | — |
| BNTC | Benitec Biopharma Inc. | $284.35M | $8.15 | — |
News headlines (Yahoo Finance, 1h cache)
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
2026-11-16 21:01 · Yahoo
Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ...
2026-11-05 07:01 · Yahoo
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
2026-11-04 21:05 · Yahoo
Emergent BioSolutions Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
2026-11-03 12:02 · Yahoo
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript
2026-11-03 05:28 · Yahoo
Emergent Biosolutions: Q3 Earnings Snapshot
2026-11-03 04:25 · Yahoo
Emergent Biosolutions Q3 Earnings Call Highlights
2026-11-02 23:13 · Yahoo
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
2026-11-02 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.